STAT2d
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
FierceBiotech2d
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...
Daiichi Sankyo’s Strategic Advancements and Innovative ADC Developments Drive Buy Rating
Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Managed Healthcare Executive2d
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...
BioPharma Dive2d
AstraZeneca, Daiichi revise approval plans for Enhertu successor
AstraZeneca and Daiichi Sankyo have changed up their approval plans for a closely watched lung cancer medicine, a decision ...
Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU Development
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
FiercePharma5d
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...